HealthCap
TypePrivate
IndustryVenture Capital
Founded1996
HeadquartersStockholm, Sweden and Lausanne, Switzerland
Total assetsEUR 1 billion
Number of employees
Approximately 25 (2023)
Websitewww.healthcap.eu

HealthCap is a specialized provider of venture capital within life sciences. HealthCap invests in innovative companies with focus on therapeutics.[1] As of 2023, HealthCap has invested in over 125 companies since inception and completed initial public offerings of more than 45 companies.[2] HealthCap has offices in Stockholm and Lausanne.

History

The firm was founded in 1996 by Björn Odlander[3] and Peder Fredrikson,[4] and the first fund was started the same year.[5] As of 2023, HealthCap has established eight funds and financed more than 125 companies, where more than 45 have been taken public on nine different markets. The most recent fund, HealthCap VIII, was established in 2019. HealthCap has approximately 25 employees out of which thirteen are partners. The team combines venture capital investing experience with competences and work experiences from small as well as large companies across the healthcare industry, spanning disciplines of scientific research, drug development, clinical practice, investment banking, and industry management.

Investments

HealthCap has raised eight main funds. Investors in HealthCap funds include, among others, European Investment Fund, Skandia Life Insurance, the 4th and 6th Swedish National Pension Funds, The Kresge Foundation, Mayo Clinic, Northwestern University, University of Michigan, Vanderbilt University and Washington University. HealthCap has committed capital exceeding EUR 1 billion.[6][7]

HealthCap invests in companies developing disruptive technologies that hold the potential to change clinical practice. Over the years HealthCap has invested in more than 125 companies. The portfolio companies have developed more than 20 pharmaceutical products and over 40 med-tech products to the market.[8] Many of these products, such as Firazyr®, Xofigo®, Tracleer®, are breakthrough therapies addressing life-threatening diseases. Examples of technologies financed by HealthCap are:

References

  1. ↑ "Portfolio companies". HealthCap.
  2. ↑ "Our Story - HealthCap". HealthCap. Retrieved 2017-07-14.
  3. ↑ "Björn Odlander". Bloomberg Businessweek. Archived from the original on January 19, 2013.
  4. ↑ "Peder Fredrikson". Bloomberg Businessweek. Archived from the original on January 10, 2013.
  5. ↑ ""Många bolag är utsvultna på kapital". Veckans Affärer".
  6. ↑ "Company Overview of HealthCap". Bloomberg Businessweek. Archived from the original on June 5, 2011.
  7. ↑ "Nordic HealthCap announces final close of its fourth biotech fund at $322m". The Alternative Assets Network. 30 November 2001.
  8. ↑ "HealthCap website". HealthCap.
  9. ↑ "Expert Insights: Johnson & Johnson's Actelion buy establishes a Clear Leader in the Pulmonary Arterial Hypertension Market". Clinical Trials Arena. 2017-08-03. Retrieved 2022-05-17.
  10. ↑ "Algeta ASA Raises Euro 23 Million in Series A Round". CRM. Archived from the original on 2016-03-04. Retrieved 2012-12-14.
  11. ↑ ""HealthCap ökar sitt ägande i Q-Med". Q-Med".
  12. ↑ "Medtronic Buying CoreValve for $700 Million+". Thomson Reuters. Archived from the original on February 4, 2013.
  13. ↑ Archived 2014-11-04 at the Wayback Machine "Wilson Therapeutics" Life Science Sweden. April 17, 2014.
  14. ↑ Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky, ML (2007). "Wilson's disease". Lancet 369 (9559): 397-408.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.